drugset / Trial / NCT05103696
A Comparative Study of Rimazolam and Propofol Combined With Etomidate in Gastroenteroscopy in Elderly Patients
RandomizedParallel-groupTriple-blindPrevention
Summary
Studies have shown that etomidate combined with propofol in gastroscopy has high safety and lower incidence of hypoxia and hypotension, suggesting the advantages of etomidate combined with propofol in elderly patients. Remimazolam Besylate is a 1.1 class new drug that acts on GABA receptors and is metabolized by plasma esterase with fast metabolism time, only 1/7 of midazolam, which may be more suitable for elderly patients. Therefore, this study intends to explore the safety and effectiveness of two sedation schemes in gastroenteroscopy for elderly patients.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2022-12-01
- Completion
- 2023-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etomidate | Small molecule | 0.1 mg/kg | — |
| Comparator | Propofol | Small molecule | 0.5 mg/kg | — |
| Subject | Remimazolam | Small molecule | 7 mg | — |
Indications
No indication recorded.